

**BILL SUMMARY**  
1<sup>st</sup> Session of the 60<sup>th</sup> Legislature

<b>Bill No.:</b>	<b>HB1389</b>
<b>Version:</b>	<b>INT</b>
<b>Request Number:</b>	<b>11233</b>
<b>Author:</b>	<b>Rep. Provenzano</b>
<b>Date:</b>	<b>2/3/2025</b>
<b>Impact:</b>	<b>\$0</b>

**Research Analysis**

HB 1389, as introduced, adds contrast-enhanced mammograms and molecular breast imaging to the list of what a diagnostic examination for breast cancer may include as well as adds that diagnostic examinations for breast cancer are in accordance with National Comprehensive Cancer Network guidelines. The measure also adds a definition of *supplemental examinations* and requires that all health benefit plans have coverage for them. This is a breast examination that is:

- used to screen for breast cancer where there is no seen or suspected abnormality; and
- based on personal or family medical history or additional factors that increase an individual's risk for breast cancer.

Prepared By: Suzie Nahach

**Fiscal Analysis**

HB 1389 requires health benefit plans to include coverage for contrast-enhanced mammograms and molecular breast imaging as part of diagnostic and supplemental examinations for breast cancer.

The Oklahoma Health Care Authority (OHCA) does not anticipate the measure to impact Medicaid costs or the state HealthChoice plan, thus having no direct impact on the state budget.

Prepared By: Alexandra Ladner, House Fiscal Staff

**Other Considerations**

None.